As cellular therapy products often cross international borders, it is important to be aware of applicable regulations in other regions. Products shipped across international borders must meet regulatory requirements of the competent authority of the exporting and importing country. Information on some non-U.S. competent authorities can be accessed via the links provided below. The information for each country is meant to serve as a resource, not a substitute for regulatory information or legal advice. Additionally, the information on this page is not updated in real-time, please contact the relevant competent authority to receive the most up-to-date information.
UK’s NICE Approves Liso-cel for NHS England
February 21, 2025
CBER Releases Updated RMAT Designation Requests, Approvals and Withdrawals
February 12, 2025
New Analysis Finds No Link Between CAR T-Cell Therapy, Secondary Cancers
February 05, 2025